![Staffan Josephson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Staffan Josephson
Directeur/Bestuurslid bij
Otre AB
Profiel
Dr. Staffan Josephson is a Principal at University of Stockholm and Senior Adviser at Investor Growth Capital AB. He is on the Board of Directors at Center for Molecular Medicine & Immunology, Inc. and Otre AB. Dr. Josephson was previously employed as a Director-Research & Development by Pharmacia AB and Senior Investment Manager by Novare Kapital AB. He also served on the board at Affibody AB, Gyros AB, HemoCue AB, and NeuroNova AB.
Actieve functies van Staffan Josephson
| Bedrijven | Functie | Begin |
|---|---|---|
University of Stockholm
 University of Stockholm Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Otre AB
 Otre AB Electronic Production EquipmentElectronic Technology Develops ozone-based sterilization technology | Directeur/Bestuurslid | - |
Eerdere bekende functies van Staffan Josephson
| Bedrijven | Functie | Einde |
|---|---|---|
Investor Growth Capital AB
 Investor Growth Capital AB Investment ManagersFinance IGC is a long-term investor with a top-down investment approach. They describe their investment attitude as patient and flexible. They are active investment partners seeking management teams operating in markets displaying sustainable growth characteristics. IGC commits themselves to board representation working closely for strategic decisions, financial and human resource allocations, potential acquisitions analyses and sources of additional capital. Their investee firms gain access to IGC's worldwide network of industry experts, advisors, and local knowledge over several geographic markets. IGC Europe invests primarily in expansion-stage firms in the technology and life sciences sectors in Northern Europe. They have an investment horizon from three to seven years. They typically invest between USD $3 million and $30 million. They acquire minority interest. IGC Asia targets expansion-stage firms in IT, software, semiconductors and Internet/media within Asia. Their investments range from USD $8 to $15 million over an investment period of three to six years. IGC US concentrates on investments in unlisted firms in healthcare and either listed or unlisted firms in IT sectors in North America. Generally, they invest in healthcare firms that have approved or marketed products. IT investments will typically be beyond the concept stage. | Corporate Officer/Principal | 31-12-2009 |
Novare Kapital AB
 Novare Kapital AB Personnel ServicesCommercial Services Provided services in the human resources area | Chief Investment Officer | - |
Pharmacia AB
 Pharmacia AB Pharmaceuticals: MajorHealth Technology Pharmaceutical concern | Hoofd Techniek/Wetenschap/O&O | - |
Center for Molecular Medicine & Immunology, Inc.
 Center for Molecular Medicine & Immunology, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in commercial physical research | Directeur/Bestuurslid | - |
Gyros AB
 Gyros AB Medical SpecialtiesHealth Technology Engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
18
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
Gyros AB
Gyros AB Medical SpecialtiesHealth Technology Engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays | Health Technology |
Affibody AB
 Affibody AB BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops radioligand therapies for cancer treatment | Health Technology |
Investor Growth Capital AB
Investor Growth Capital AB Investment ManagersFinance IGC is a long-term investor with a top-down investment approach. They describe their investment attitude as patient and flexible. They are active investment partners seeking management teams operating in markets displaying sustainable growth characteristics. IGC commits themselves to board representation working closely for strategic decisions, financial and human resource allocations, potential acquisitions analyses and sources of additional capital. Their investee firms gain access to IGC's worldwide network of industry experts, advisors, and local knowledge over several geographic markets. IGC Europe invests primarily in expansion-stage firms in the technology and life sciences sectors in Northern Europe. They have an investment horizon from three to seven years. They typically invest between USD $3 million and $30 million. They acquire minority interest. IGC Asia targets expansion-stage firms in IT, software, semiconductors and Internet/media within Asia. Their investments range from USD $8 to $15 million over an investment period of three to six years. IGC US concentrates on investments in unlisted firms in healthcare and either listed or unlisted firms in IT sectors in North America. Generally, they invest in healthcare firms that have approved or marketed products. IT investments will typically be beyond the concept stage. | Finance |
HemoCue AB
 HemoCue AB Medical SpecialtiesHealth Technology Develops, produces, and markets medical diagnostic products for point of care testing | Health Technology |
Pharmacia AB
Pharmacia AB Pharmaceuticals: MajorHealth Technology Pharmaceutical concern | Health Technology |
Novare Kapital AB
Novare Kapital AB Personnel ServicesCommercial Services Provided services in the human resources area | Commercial Services |
Otre AB
Otre AB Electronic Production EquipmentElectronic Technology Develops ozone-based sterilization technology | Electronic Technology |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Health Technology |
University of Stockholm
University of Stockholm Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Center for Molecular Medicine & Immunology, Inc.
Center for Molecular Medicine & Immunology, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in commercial physical research | Commercial Services |
